What it's for (Indications)
- Carbamazepine is indicated for the treatment of epilepsy and bipolar disorder (mood disorder), particularly in patients who do not respond well to lithium.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage must be individualized based on the patient's condition, age, and response to treatment. A low initial daily dosage with gradual increases is advised until adequate control is achieved. Once controlled, the dosage may be reduced very gradually to the minimum effective level. Typically, 1-2 tablets are taken every day with a glass of water at the same time. The medication should be taken with meals. Monitoring of blood levels is recommended to optimize efficacy and safety. Carbamazepine suspension should not be administered simultaneously with other liquid medications or diluents (e.g., liquid chlorpromazine or thioridazine) due to the risk of precipitate formation. Abrupt discontinuation is not recommended and should be avoided. Full therapeutic effects may take 1-2 weeks. |
Safety & Warnings
Common Side Effects
- Common adverse reactions, especially during initial therapy, include dizziness, drowsiness, unsteadiness (ataxia), nausea, vomiting, upset stomach, diplopia (double vision), and dry mouth.
- More serious or less common effects include hypersensitivity reactions, heart problems (low blood pressure, slow heartbeat), liver function impairment (jaundice, hepatitis), deranged blood tests, anemia, confusion, psychosis, and suicidal thoughts.
- Long-term use may lead to osteopenia (increased risk of bone fractures) and osteoporosis (weak, brittle bones).
- Severe hematologic adverse reactions include aplastic anemia, agranulocytosis, pancytopenia, bone marrow depression, thrombocytopenia, leukopenia, leukocytosis, eosinophilia, acute intermittent porphyria, variegate porphyria, and porphyria cutanea.
Serious Warnings
- Black Box Warning: SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH CARBAMAZEPINE. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A S
- Serious Dermatologic Reactions: Patients should be monitored for severe dermatologic reactions, including Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS).
- The risk is significantly higher in some Asian populations due to the HLA-B*1502 allele.
- Hematologic Effects: The drug may cause bone marrow suppression, aplastic anemia, agranulocytosis, and other severe blood dyscrasias.
- Regular monitoring of blood tests is crucial.
- Liver Toxicity: May cause jaundice or hepatitis; periodical liver function tests are required.
- Use with caution in patients with hepatic disorders.
- Cardiovascular Effects: Associated with low blood pressure, slow heartbeat, and other heart problems.
- Should be avoided in patients with A-V conduction abnormalities unless paced.
- Patients with severe cardiovascular disease should consult their doctor.
- Neuropsychiatric Effects: May cause dizziness, drowsiness, confusion, psychosis, and suicidal thoughts.
- Patients should be monitored for significant behavioral changes.
- Avoid driving or operating machinery if affected.
- Abrupt Discontinuation: Abrupt discontinuation of carbamazepine can lead to seizures or even status epilepticus.
- The medication should be withdrawn gradually under medical supervision.
- Drug Interactions: May affect the metabolism and reduce the efficacy of other medicines, such as acetaminophen and oral contraceptives (combined oral contraceptives, progesterone-only pills, vaginal ring, contraceptive patches, emergency contraceptives); alternate contraception methods should be discussed.
- Grapefruit juice can increase carbamazepine concentration; its consumption should be avoided.
- Carbamazepine suspension should not be administered simultaneously with other liquid medications or diluents (e.
- g.
- , liquid chlorpromazine or thioridazine) due to precipitate formation.
- Pregnancy and Lactation: Not recommended for use by pregnant females, especially in the first trimester, due to potential birth defects or termination of pregnancy.
- Passes into breast milk, and its effects on nursing infants are unknown; generally avoided in breastfeeding women.
- Consult a doctor if pregnant, planning pregnancy, or breastfeeding.
- Renal Function: Use with caution in patients with renal disorders; consultation with a doctor is advised.
- Monitoring: Regular monitoring of blood levels, liver function tests, and blood tests (including bone health checks for long-term use) is recommended.
- Storage: Store at room temperature, away from excess heat and moisture.
How it Works (Mechanism of Action)
Carbamazepine exerts its primary therapeutic effects predominantly through the blockade of voltage-gated sodium channels in neuronal membranes. By binding to and stabilizing the inactivated state of these channels, carbamazepine effectively reduces the rapid and repetitive firing of action potentials in hyperexcitable neurons. This action diminishes the sustained high-frequency discharge that is characteristic of epileptic seizures and plays a crucial role in preventing the generation and spread of seizure activity within the central nervous system. Furthermore, by modulating neuronal excitability, this mechanism also contributes to its efficacy in neuropathic pain (e.g., trigeminal neuralgia) and mood stabilization in bipolar disorder. While its main action is on sodium channels, carbamazepine may also influence other neurotransmitter systems and ion channels, including effects on potassium channels, calcium channels, and the GABAergic system, albeit to a lesser extent, contributing to its broad pharmacological profile.